

Dept. of External Affairs
Min. des Affaires extérieures
OTTAWA

JUL 28 1997

RETURN TO DEPARTMENT
RETOURNER A LA BUREAULIBRARY
DU MINISTERE

Moving north: IVAX Corporation

transfers some manufacturing muscle from the U.S.

to Quebec

Miami-based IVAX Corporation, a manufacturer of generic pharmaceuticals, is closing two of its U.S. plants, one in Florida, the other in Louisiana, to consolidate manufacturing in Kirkland, Quebec. In so doing, it will maintain existing jobs at Kirkland and possibly add more in the future.

IVAX is moving its manufacturing operations into a 275,000 square foot plant that the company purchased from Glaxo Wellcome Inc. in 1996. The facility came fully equipped with production machinery and a staff of some 165 highly trained employees.

The move to Kirkland is part of a widespread restructuring of manufacturing facilities that IVAX is carrying out to reduce costs and enhance operating efficiencies.

"The Kirkland facility has the capacity to manufacture a wide range of pharmaceutical products, including injectable preparations — an important manufacturing capability that we do not presently possess."

IVAX Chairman and CEO, Phillip Frost, M.D., describes the northward move of the two facilities as "a linchpin of our plan to consolidate manufacturing facilities.

"The Kirkland facility has the capacity to manufacture a wide range of pharmaceutical products, including injectable preparations — an important manufacturing capability that we do not presently possess. The facility's advanced, efficient equipment and design should ultimately lower the overall manufacturing costs of the products we will produce there." ♦

